Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a gentle electric pulse fix an irregular heartbeat?

NCT ID NCT07779369

Disease control Sponsor: Radboud University Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 21, 2026 · Last updated Aug 21, 2026

Summary

This trial investigates whether a new technique called pulsed field ablation (PFA) can more effectively treat atrial fibrillation, a common heart rhythm problem. The procedure uses short electrical pulses to create precise lesions in the heart tissue, aiming to block faulty signals while sparing nearby structures. Participants will undergo PFA with the VARIPULSE catheter, followed by a re-mapping procedure after three months to check if the isolation holds. The study also uses MRI to see if imaging can predict long-term success, potentially improving future treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Pulsed field ablation (PFA) using the VARIPULSE catheter, a device that delivers short electrical pulses to create heart tissue lesions.
What this could lead to
If successful, this could show that pulsed field ablation provides more durable isolation of the pulmonary veins than current heat-based methods, potentially reducing the need for repeat procedures in atrial fibrillation.
What could go wrong
This is a relatively small study (40 participants) and early-stage, so results may not apply broadly. The procedure carries standard risks of catheter ablation, such as bleeding, infection, or heart damage, and the long-term durability is still unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ≥18 years of age * AF and eligible for index PVI according to current ESC guidelines Exclusion Criteria: * Unwilling or unable to give written informed consent * Prior left atrial ablation * Other left atrial arrhythmias including atrial flutters * Prior left atrial surgery * Severe mitral valve regurgitation * Contraindication for gadolinium-based contrast agents * Contraindications for CMR (including metallic implants, cochlear implants, cardiac devices, neurostimulation systems, claustrophobia) * Renal insufficiency (eGFR \< 30 ml/min)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrial fibrillation (AF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrial fibrillation (AF)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.